ankyrin repeat domain 20 family member A19, pseudogeneGenealiases: []
Q-omics provides the consensus-scored ANKRD20A19P profile across patient tissues and cancer cell-line models. ANKRD20A19P expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, ANKRD20A19P is differentially expressed in 8, with the highest sampling consensus in COAD. Additionally, ANKRD20A19P RNA expression shows 11,056 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight COAD, and THYM as cancer lineages where ANKRD20A19P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ANKRD20A19P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ANKRD20A19P survival associations across molecular data types. ANKRD20A19P RNA expression shows survival associations in the most cancer types (18), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ANKRD20A19P RNA expression–survival associations across cancer types. High ANKRD20A19P expression shows unfavorable associations in COAD, KICH and KIRC, but favorable associations in KIRP, CESC and UCS. The COAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify COAD as the clearest survival context for ANKRD20A19P RNA expression.
This table summarizes ANKRD20A19P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for ANKRD20A19P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ANKRD20A19P shows lower tumor expression in KICH and higher tumor expression in COAD, BRCA, THCA, LUSC and HNSC. The COAD box plot shows higher ANKRD20A19P RNA expression in tumor versus normal tissue (log2 FC = +0.096, t-test p < 0.001).
This table shows molecular features associated with ANKRD20A19P in patient tissues and cancer cell lines. In patient samples, ANKRD20A19P shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, ANKRD20A19P RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST.
